BioSpace News Archive

RES, the nation’s largest environmental solutions provider, has received approval from the U.S. Fish & Wildlife Service (USFWS) for Pennsylvania’s first bat conservation bank.

Aimmune Therapeutics, Inc. announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for AR101, an investigational biologic oral immunotherapy for the treatment of peanut allergy in children and adolescents ages 4–17

Health Canada is warning Canadians that Pace, a shot-sized drink that is being promoted as an alcohol substitute, contains an active ingredient—5-methoxy-2-aminoindane (MEAI)—that is similar in structure to amphetamines and may pose serious health risks

Medivir AB today announced that the first patient in the phase ll part of the BPT-201 study of birinapant in combination with Keytruda® (pembrolizumab) has been dosed.

CStone Pharmaceuticals (“CStone”) today announced the successful enrollment and dosing of the first three patients in a Phase I clinical trial in the United States for CS1001, China’s first fully human and full-length anti-PD-L1 monoclonal antibody.

Donation aimed at raising awareness of older adult hunger and food insecurity in Ohio

Viriom, Inc. announced today that it plans to report results from its Phase 1b clinical trial of once weekly dosing of oral elsulfavirine (Elida®, VM1500), a potent long acting nonnucleoside reverse transcriptase inhibitor (NNRTI) in HIV-uninfected volunteers in March 2019.

Health care generates vast amounts of data that have the potential to drive medical research and improve health, but unlocking the power of those data for the greater good is often slow and challenging.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for solriamfetol as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).

Exemplar Genetics, a subsidiary of Intrexon Corporation (NASDAQ: XON) and market leader in the development of genetically engineered miniswine as models of human disease, and Mayo Clinic have launched a joint venture focused on the development of a high quality source of human liver cells or hepatocytes (HHCs).